Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein Occlusion
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing
administered with or without adjunctive laser treatment versus laser photocoagulation (the
current standard of care) up to Month 6 in patients with visual impairment due to ME
secondary to BRVO. Additionally the results of this study will provide long-term (24-month)
safety and efficacy data for ranibizumab, administered with or without adjunctive laser
treatment in this indication.